Compass Pathways delays key Phase 3 psilocybin readouts, spurring 30% layoffs

Compass Pathways is pushing back the timelines of two key pivotal readouts, delaying data for a psilocybin program that's one of the leaders in psychedelic drug development. The first Phase 3 pivotal study, COMP005, is ...